Tags

Type your tag names separated by a space and hit enter

Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February.
Euro Surveill. 2021 03; 26(11)ES

Abstract

The SARS-CoV-2 B.1.1.7 variant of concern (VOC) is increasing in prevalence across Europe. Accurate estimation of disease severity associated with this VOC is critical for pandemic planning. We found increased risk of death for VOC compared with non-VOC cases in England (hazard ratio: 1.67; 95% confidence interval: 1.34-2.09; p < 0.0001). Absolute risk of death by 28 days increased with age and comorbidities. This VOC has potential to spread faster with higher mortality than the pandemic to date.

Authors+Show Affiliations

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.The Phoenix Partnership (TPP), TPP House, Leeds, United Kingdom.The Phoenix Partnership (TPP), TPP House, Leeds, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.COVID-19 Outbreak Surveillance Team, Public Health England, London, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.The Phoenix Partnership (TPP), TPP House, Leeds, United Kingdom.The Phoenix Partnership (TPP), TPP House, Leeds, United Kingdom.The Phoenix Partnership (TPP), TPP House, Leeds, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.These authors contributed equally. The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.These authors contributed equally. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.These authors contributed equally. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33739254

Citation

Grint, Daniel J., et al. "Case Fatality Risk of the SARS-CoV-2 Variant of Concern B.1.1.7 in England, 16 November to 5 February." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 26, no. 11, 2021.
Grint DJ, Wing K, Williamson E, et al. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Euro Surveill. 2021;26(11).
Grint, D. J., Wing, K., Williamson, E., McDonald, H. I., Bhaskaran, K., Evans, D., Evans, S. J., Walker, A. J., Hickman, G., Nightingale, E., Schultze, A., Rentsch, C. T., Bates, C., Cockburn, J., Curtis, H. J., Morton, C. E., Bacon, S., Davy, S., Wong, A. Y., ... Eggo, R. M. (2021). Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 26(11). https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100256
Grint DJ, et al. Case Fatality Risk of the SARS-CoV-2 Variant of Concern B.1.1.7 in England, 16 November to 5 February. Euro Surveill. 2021;26(11) PubMed PMID: 33739254.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. AU - Grint,Daniel J, AU - Wing,Kevin, AU - Williamson,Elizabeth, AU - McDonald,Helen I, AU - Bhaskaran,Krishnan, AU - Evans,David, AU - Evans,Stephen Jw, AU - Walker,Alex J, AU - Hickman,George, AU - Nightingale,Emily, AU - Schultze,Anna, AU - Rentsch,Christopher T, AU - Bates,Chris, AU - Cockburn,Jonathan, AU - Curtis,Helen J, AU - Morton,Caroline E, AU - Bacon,Sebastian, AU - Davy,Simon, AU - Wong,Angel Ys, AU - Mehrkar,Amir, AU - Tomlinson,Laurie, AU - Douglas,Ian J, AU - Mathur,Rohini, AU - Blomquist,Paula, AU - MacKenna,Brian, AU - Ingelsby,Peter, AU - Croker,Richard, AU - Parry,John, AU - Hester,Frank, AU - Harper,Sam, AU - DeVito,Nicholas J, AU - Hulme,Will, AU - Tazare,John, AU - Goldacre,Ben, AU - Smeeth,Liam, AU - Eggo,Rosalind M, PY - 2021/3/19/entrez PY - 2021/3/20/pubmed PY - 2021/3/25/medline KW - CFR KW - COVID-19 KW - Case fatality risk KW - Coronavirus KW - Mortality KW - SARS-CoV-2 KW - Variant of concern JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill VL - 26 IS - 11 N2 - The SARS-CoV-2 B.1.1.7 variant of concern (VOC) is increasing in prevalence across Europe. Accurate estimation of disease severity associated with this VOC is critical for pandemic planning. We found increased risk of death for VOC compared with non-VOC cases in England (hazard ratio: 1.67; 95% confidence interval: 1.34-2.09; p < 0.0001). Absolute risk of death by 28 days increased with age and comorbidities. This VOC has potential to spread faster with higher mortality than the pandemic to date. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/33739254/Case_fatality_risk_of_the_SARS_CoV_2_variant_of_concern_B_1_1_7_in_England_16_November_to_5_February_ L2 - http://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.11.2100256 DB - PRIME DP - Unbound Medicine ER -